In this episode of the podcast, Joe interviews Greg McKee: Chairman and CEO of Tryp Therapeutics, an early-stage biotech company focusing on nociplastic pain and how it could be alleviated through the brain rewiring often possible in the psychedelic experience. They are first looking at psychedelics for chronic pain and eating disorders, and when this podcast was recorded, had just received FDA clearance to begin a fibromyalgia study at the University of Michigan (with studies on phantom limb pain, complex regional pain syndrome, binge eating disorder, and hypothalamic obesity likely coming after). McKee discusses the origins of Tryp, the benefits of using synthetics, the positives to take away from Compass Pathways’ preliminary psilocybin Phase 2B trial results, and why a lot of early psychedelic investors may be mistakenly panicking.

The post PT283 – Greg McKee – Nociplastic Pain and Psychedelics appeared first on Psychedelics Today.

Previous articlePsychedelic Research and Clinical Trials in 2021
Next articleWesana Health Granted US FDA Pre-IND Meeting for SANA-013